DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism
Parkinson’s disease has a long premotor phase with ongoing dopaminergic degeneration, yet its compensatory mechanisms remain unclear. Using a rat model with A53T α-synuclein overexpression in the substantia nigra, we analyzed striatal synaptic changes at 72 h, 1, 2, and 4 weeks post-inoculation, before motor signs appeared. Dopamine concentration decreased from 72 h, and chemical long-term potentiation was simultaneously inhibited, partially recovering by 4 weeks. At this time point, dopaminergic degeneration and post-synaptic morphological and ultrastructural dendritic spine remodelling became significant. These changes included a reduction in thin dendritic spines, an increase in mushroom spine head volume, a decrease in smooth endoplasmic reticulum-containing spines, and an increase in dendritic branching. In conclusion, impaired striatal dopaminergic neurotransmisson diminishes striatal synaptic plasticity, which can be partially restored through complex structural changes in striatal spines. These adaptations might represent fundamental homeostatic mechanisms regulating synaptic function during the premotor stage of Parkinson’s disease. (Figure presented.), This study was funded by the Instituto de Salud Carlos III (ISCIII) through the projects PI14/00763 and PI19/01915, Co-funded by the European Regional Development fund ‘A way to make Europe’. LM-G held a Predoctoral Research Fellowship from the University of the Basque Country (UPV/EHU) and two travel grants from the UPV/EHU and Boehringer Ingelheim, respectively, to perform consecutive research stays at Columbia University. AB-I held a Predoctoral Research Fellowship from the Government of the Basque Country. J.B held a Miguel Servet Program CP19/00200 from Instituto de Salud Carlos III. J.B and A.R-S are funded by Aligning Science Across Parkinson’s [ASAP-020505] through the Michael J. Fox Foundation for Parkinson’s Research (MJFF).The authors would like to thank the CIMA-Universidad Navarra, University of the Basque Country (UPV/EHU), Columbia University, and Boehringer Ingelheim for their support and use of their infrastructures.